Literature DB >> 22127610

Receptor-guided 3D-QSAR approach for the discovery of c-kit tyrosine kinase inhibitors.

Anna Maria Almerico1, Marco Tutone, Antonino Lauria.   

Abstract

Studies of the the three-dimensional quantitative structure-activity relationships for ninety-five c-kit tyrosine kinase inhibitors were performed. Based on a co-crystallized compound (1 T46), known inhibitors were aligned with c-kit by induced-fit docking, and multiple training/test set splitting was performed to validate the selected pharmacophore model. The best pharmacophore model consisted of five features: one hydrogen-bond donor and four aromatic rings. Reliable statistics were obtained (R(2) = 0.95, R(pred) (2) = 0.75), and the model was validated by using it to select c-kit inhibitors from a database; 82.1% of the hits it retrieved were active. Accordingly, our model can be reliably used to identify new c-kit inhibitors, and can provide useful information when designing new inhibitors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22127610     DOI: 10.1007/s00894-011-1304-0

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  14 in total

1.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results.

Authors:  Steven L Dixon; Alexander M Smondyrev; Eric H Knoll; Shashidhar N Rao; David E Shaw; Richard A Friesner
Journal:  J Comput Aided Mol Des       Date:  2006-11-24       Impact factor: 3.686

2.  Discovery of amido-benzisoxazoles as potent c-Kit inhibitors.

Authors:  Roxanne K Kunz; Shannon Rumfelt; Ning Chen; Dawei Zhang; Andrew S Tasker; Roland Bürli; Randall Hungate; Violeta Yu; Yen Nguyen; Douglas A Whittington; Kristin L Meagher; Matthew Plant; Yanyan Tudor; Michael Schrag; Yang Xu; Gordon Y Ng; Essa Hu
Journal:  Bioorg Med Chem Lett       Date:  2008-07-31       Impact factor: 2.823

Review 3.  Early signaling pathways activated by c-Kit in hematopoietic cells.

Authors:  D Linnekin
Journal:  Int J Biochem Cell Biol       Date:  1999-10       Impact factor: 5.085

4.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

Authors:  M C Heinrich; D J Griffith; B J Druker; C L Wait; K A Ott; A J Zigler
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

5.  Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.

Authors:  W L Wang; M E Healy; M Sattler; S Verma; J Lin; G Maulik; C D Stiles; J D Griffin; B E Johnson; R Salgia
Journal:  Oncogene       Date:  2000-07-20       Impact factor: 9.867

6.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

7.  Aberrant activation of c-kit protects colon carcinoma cells against apoptosis and enhances their invasive potential.

Authors:  G Bellone; A Carbone; N Sibona; O Bosco; D Tibaudi; C Smirne; T Martone; C Gramigni; M Camandona; G Emanuelli; U Rodeck
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

Review 8.  Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy.

Authors:  Kari K Eklund
Journal:  Immunol Rev       Date:  2007-06       Impact factor: 12.988

9.  Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.

Authors:  Michele H Potashman; James Bready; Angela Coxon; Thomas M DeMelfi; Lucian DiPietro; Nicholas Doerr; Daniel Elbaum; Juan Estrada; Paul Gallant; Julie Germain; Yan Gu; Jean-Christophe Harmange; Stephen A Kaufman; Rick Kendall; Joseph L Kim; Gondi N Kumar; Alexander M Long; Seshadri Neervannan; Vinod F Patel; Anthony Polverino; Paul Rose; Simon van der Plas; Douglas Whittington; Roger Zanon; Huilin Zhao
Journal:  J Med Chem       Date:  2007-08-15       Impact factor: 7.446

10.  3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases.

Authors:  Zhiqin Ji; Asma A Ahmed; Daniel H Albert; Jennifer J Bouska; Peter F Bousquet; George A Cunha; Gilbert Diaz; Keith B Glaser; Jun Guo; Christopher M Harris; Junling Li; Patrick A Marcotte; Maria D Moskey; Tetsuro Oie; Lori Pease; Nirupama B Soni; Kent D Stewart; Steven K Davidsen; Michael R Michaelides
Journal:  J Med Chem       Date:  2008-02-09       Impact factor: 7.446

View more
  3 in total

1.  In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening.

Authors:  Prashant Chaudhari; Sanjay Bari
Journal:  Mol Divers       Date:  2015-09-28       Impact factor: 2.943

2.  Pharmacophore-Based Design of New Chemical Scaffolds as Translational Readthrough-Inducing Drugs (TRIDs).

Authors:  Marco Tutone; Ivana Pibiri; Riccardo Perriera; Ambra Campofelice; Giulia Culletta; Raffaella Melfi; Andrea Pace; Anna Maria Almerico; Laura Lentini
Journal:  ACS Med Chem Lett       Date:  2020-02-18       Impact factor: 4.345

3.  Molecular dynamics, dynamic site mapping, and highthroughput virtual screening on leptin and the Ob receptor as anti-obesity target.

Authors:  Marco Tutone; Licia Pantano; Antonino Lauria; Anna Maria Almerico
Journal:  J Mol Model       Date:  2014-05-06       Impact factor: 1.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.